BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 21118481)

  • 1. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
    Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
    BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
    Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
    Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
    Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
    BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
    Alvarez C; Aravena A; Tapia T; Rozenblum E; Solís L; Corvalán A; Camus M; Alvarez M; Munroe D; Maass A; Carvallo P
    BMC Cancer; 2016 Mar; 16():219. PubMed ID: 26979459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
    Massink MP; Kooi IE; van Mil SE; Jordanova ES; Ameziane N; Dorsman JC; van Beek DM; van der Voorn JP; Sie D; Ylstra B; van Deurzen CH; Martens JW; Smid M; Sieuwerts AM; de Weerd V; Foekens JA; van den Ouweland AM; van Dyk E; Nederlof PM; Waisfisz Q; Meijers-Heijboer H
    Mol Oncol; 2015 Apr; 9(4):877-88. PubMed ID: 25616998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
    Liu X; Holstege H; van der Gulden H; Treur-Mulder M; Zevenhoven J; Velds A; Kerkhoven RM; van Vliet MH; Wessels LF; Peterse JL; Berns A; Jonkers J
    Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12111-6. PubMed ID: 17626182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
    Severson TM; Peeters J; Majewski I; Michaut M; Bosma A; Schouten PC; Chin SF; Pereira B; Goldgraben MA; Bismeijer T; Kluin RJ; Muris JJ; Jirström K; Kerkhoven RM; Wessels L; Caldas C; Bernards R; Simon IM; Linn S
    Mol Oncol; 2015 Oct; 9(8):1528-38. PubMed ID: 26004083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
    Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
    PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
    Prat A; Cruz C; Hoadley KA; Díez O; Perou CM; Balmaña J
    Breast Cancer Res Treat; 2014 Aug; 147(1):185-91. PubMed ID: 25048467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
    Zhang M; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2012 Feb; 132(1):335-40. PubMed ID: 22116506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Holm K; Hegardt C; Gunnarsson H; Fagerholm R; Strand C; Agnarsson BA; Kilpivaara O; Luts L; Heikkilä P; Aittomäki K; Blomqvist C; Loman N; Malmström P; Olsson H; Johannsson OT; Arason A; Nevanlinna H; Barkardottir RB; Borg A
    Breast Cancer Res; 2010; 12(3):R42. PubMed ID: 20576095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
    Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
    Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
    Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
    BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
    Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
    Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
    Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
    Manié E; Vincent-Salomon A; Lehmann-Che J; Pierron G; Turpin E; Warcoin M; Gruel N; Lebigot I; Sastre-Garau X; Lidereau R; Remenieras A; Feunteun J; Delattre O; de Thé H; Stoppa-Lyonnet D; Stern MH
    Cancer Res; 2009 Jan; 69(2):663-71. PubMed ID: 19147582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.